Besides TAA expressed in malignant GBM cells, antigens expressed by vascular endothelial cells [e.g., vasculature endothelial growth factor receptor 2 (VEGFR2)] of the tumor vasculature or by other stromal cells are potential targets for T-cell therapy. This evidence concerns the gene KDR and neoplasm.